Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

BACKGROUND Uterine cancer is the fourth most common malignancy in women, and uterine serous carcinoma is the most aggressive subtype. However, the molecular pathogenesis of uterine serous carcinoma is largely unknown. We analyzed the genomes of uterine serous carcinoma samples to better understand the molecular genetic characteristics of this cancer. METHODS Whole-exome sequencing was performed on 10 uterine serous carcinomas and the matched normal blood or tissue samples. Somatically acquired sequence mutations were further verified by Sanger sequencing. The most frequent molecular genetic changes were further validated by Sanger sequencing in 66 additional uterine serous carcinomas and in nine serous endometrial intraepithelial carcinomas (the preinvasive precursor of uterine serous carcinoma) that were isolated by laser capture microdissection. In addition, gene copy number was characterized by single-nucleotide polymorphism (SNP) arrays in 23 uterine serous carcinomas, including 10 that were subjected to whole-exome sequencing. RESULTS We found frequent somatic mutations in TP53 (81.6%), PIK3CA (23.7%), FBXW7 (19.7%), and PPP2R1A (18.4%) among the 76 uterine serous carcinomas examined. All nine serous carcinomas that had an associated serous endometrial intraepithelial carcinoma had concordant PIK3CA, PPP2R1A, and TP53 mutation status between uterine serous carcinoma and the concurrent serous endometrial intraepithelial carcinoma component. DNA copy number analysis revealed frequent genomic amplification of the CCNE1 locus (which encodes cyclin E, a known substrate of FBXW7) and deletion of the FBXW7 locus. Among 23 uterine serous carcinomas that were subjected to SNP array analysis, seven tumors with FBXW7 mutations (four tumors with point mutations, three tumors with hemizygous deletions) did not have CCNE1 amplification, and 13 (57%) tumors had either a molecular genetic alteration in FBXW7 or CCNE1 amplification. Nearly half of these uterine serous carcinomas (48%) harbored PIK3CA mutation and/or PIK3CA amplification. CONCLUSION Molecular genetic aberrations involving the p53, cyclin E-FBXW7, and PI3K pathways represent major mechanisms in the development of uterine serous carcinoma.

[1]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[2]  C. Isacson,et al.  Early Uterine Serous Carcinoma: Clonal Origin of Extrauterine Disease , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[3]  U. Moll,et al.  Loss of p53 function in uterine papillary serous carcinoma. , 1998, Human pathology.

[4]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[5]  Kenneth H. Buetow,et al.  Bioinformatics Applications Note Sequence Analysis Bambino: a Variant Detector and Alignment Viewer for Next-generation Sequencing Data in the Sam/bam Format , 2022 .

[6]  Tatiana A. Tatusova,et al.  NCBI Reference Sequences: current status, policy and new initiatives , 2008, Nucleic Acids Res..

[7]  Matthew W. Wilson,et al.  A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses , 2011, Nature.

[8]  Frank McCormick,et al.  A Critical Role for FBXW8 and MAPK in Cyclin D1 Degradation and Cancer Cell Proliferation , 2006, PloS one.

[9]  J. Kornbluth,et al.  NK Lytic-Associated Molecule, Involved in NK Cytotoxic Function, Is an E3 Ligase1 , 2006, The Journal of Immunology.

[10]  L. Szekely,et al.  Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human uridine kinase/uracil phosphoribosyltransferase , 2002, BMC Cell Biology.

[11]  L. Ellenson,et al.  Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. , 2009, Gynecologic oncology.

[12]  S. Reed,et al.  FBXW7/hCDC4 is a general tumor suppressor in human cancer. , 2007, Cancer research.

[13]  I. Shih,et al.  Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. , 2009, Cancer research.

[14]  S. Elledge,et al.  Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Kornbluth,et al.  Downregulation of uridine-cytidine kinase like-1 decreases proliferation and enhances tumor susceptibility to lysis by apoptotic agents and natural killer cells , 2009, Apoptosis.

[16]  B. Clurman,et al.  FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation , 2008, Nature Reviews Cancer.

[17]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[18]  Martin A. Nowak,et al.  The significance of unstable chromosomes in colorectal cancer , 2003, Nature Reviews Cancer.

[19]  O. Sangfelt,et al.  The Fbxw7/hCdc4 tumor suppressor in human cancer. , 2008, Cancer letters.

[20]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[21]  R. Slebos,et al.  The frequency of p53, k‐ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma , 2000, Cancer.

[22]  I. Shih,et al.  Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma , 2011, The Journal of pathology.

[23]  I. Shih,et al.  DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma , 2010, Clinical Cancer Research.

[24]  I. Shih,et al.  TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high‐grade serous carcinoma—evidence supporting the clonal relationship of the two lesions , 2012, The Journal of pathology.

[25]  M. Sherman,et al.  Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. , 1995, Human pathology.

[26]  M. Sherman,et al.  p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. , 1995, Human pathology.

[27]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[28]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.

[29]  Kathleen R. Cho,et al.  p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. , 1997, The American journal of pathology.

[30]  E. S. Venkatraman,et al.  A faster circular binary segmentation algorithm for the analysis of array CGH data , 2007, Bioinform..

[31]  R. Hruban,et al.  BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. , 2003, The American journal of pathology.

[32]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[33]  Adam R. Johnson,et al.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.

[34]  Akinobu Matsumoto,et al.  Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis , 2007, The Journal of experimental medicine.

[35]  M. J. Fry,et al.  The phosphoinositide (PI) 3-kinase family , 2003, Journal of Cell Science.

[36]  K. Nakayama,et al.  Fbxw7 in cell cycle exit and stem cell maintenance: Insight from gene-targeted mice , 2008, Cell cycle.

[37]  K. Kinzler,et al.  Low‐grade serous carcinomas of the ovary contain very few point mutations , 2012, The Journal of pathology.

[38]  I. Shih,et al.  Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma , 2011, The American journal of surgical pathology.

[39]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[40]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[41]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[42]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[43]  I. Tomlinson,et al.  F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. , 2010, Gastroenterology.